Beam Looks Beyond Liver With Guide Therapeutics Acquisition
Company Pays $120m Upfront
You may also be interested in...
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
The company also raised a $70m Series A round and is looking to develop “off-the-shelf” gene therapies adapted to settings with fewer resources.